<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03826160</url>
  </required_header>
  <id_info>
    <org_study_id>2018P001792</org_study_id>
    <nct_id>NCT03826160</nct_id>
  </id_info>
  <brief_title>Growth Hormone Dynamics and Cardiac Steatosis in HIV</brief_title>
  <official_title>Role of Growth Hormone in the Pathogenesis and Treatment of Cardiac Steatosis and Diastolic Dysfunction in HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac steatosis is increased among individuals with HIV, and may predispose to cardiac
      mechanical dysfunction and subsequent heart failure. The pathogenesis and treatment of
      cardiac steatosis is not well understood. The investigators have previously shown that
      perturbed growth hormone (GH) secretion in HIV contributes to ectopic fat accumulation in the
      viscera and the liver. Moreover, the investigators have found that augmentation of endogenous
      GH secretion with the FDA-approved medication tesamorelin reduces visceral and hepatic fat.
      In this longitudinal observational study, the investigators will examine patients with HIV
      and abdominal fat accumulation who either plan or do not plan to initiate tesamorelin
      prescribed clinically. The investigators hypothesize that blunted GH secretion in HIV is
      associated with cardiac steatosis. The investigators also hypothesize that use of tesamorelin
      for 6 months is associated with a reduction in intramyocardial fat and preserved cardiac
      function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intramyocardial lipid content</measure>
    <time_frame>6 months</time_frame>
    <description>Measure of fat content within cardiac muscle as assessed by cardiac magnetic resonance spectroscopy (MRS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circumferential diastolic strain rate</measure>
    <time_frame>6 months</time_frame>
    <description>Measure of diastolic function as assessed by cardiac magnetic resonance imaging (MRI)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>Lipodystrophy</condition>
  <condition>Cardiac Disease</condition>
  <arm_group>
    <arm_group_label>Tesamorelin</arm_group_label>
    <description>Individuals who plan to initiate tesamorelin clinically</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Treatment</arm_group_label>
    <description>Individuals who decline to initiate tesamorelin despite a clinical indication</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples for subsequent processing
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV patients, age 40-70 years old, with abdominal fat accumulation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, ages 40-70 years

          -  Documented HIV infection on stable antiretroviral therapy for ≥ 3 months

          -  Abdominal obesity with waist circumference ≥ 102 cm in men, ≥ 88 cm in women

          -  Indication for tesamorelin per clinical judgment

        Exclusion Criteria:

          -  CD4 &lt; 100 cells/mm3 or HIV viral load &gt; 400 copies/mL

          -  Current active AIDS-defining illness

          -  History or symptoms consistent with heart failure

          -  Standard contraindications to MRI including severe allergy to gadolinium

          -  Glomerular filtration rate (eGFR) &lt; 45 mL/min/1.73 m2 within one month of MRI study

          -  Use of growth hormone-releasing hormone (GHRH) or growth hormone (GH) within the past
             6 months

          -  HbA1c &gt; 7%, chronic insulin use within the past 6 months, and/or change in
             anti-diabetic agents within the past 3 months

          -  Change in statin therapy within the past 3 months

          -  Chronic corticosteroid use except intermittent topic steroid creams or inhalers

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Steven Grinspoon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lindsay T Fourman, MD</last_name>
    <phone>617-643-4590</phone>
    <email>lfourman@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steven Grinspoon, MD</last_name>
    <phone>617-724-9109</phone>
    <email>sgrinspoon@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Grinspoon, MD</last_name>
      <phone>617-724-9109</phone>
      <email>sgrinspoon@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Grinspoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2019</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven K. Grinspoon, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

